| Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine M Rubinstein, TJ Phillips, JR Bunzow, TL Falzone, G Dziewczapolski, ... Cell 90 (6), 991-1001, 1997 | 598 | 1997 |
| Postural deformities in Parkinson's disease KM Doherty, BP van de Warrenburg, MC Peralta, L Silveira-Moriyama, ... The Lancet Neurology 10 (6), 538-549, 2011 | 561 | 2011 |
| Levodopa in the treatment of Parkinson's disease: current controversies CW Olanow, Y Agid, Y Mizuno, A Albanese, U Bonucelli, P Damier, ... Movement disorders 19 (9), 997-1005, 2004 | 503 | 2004 |
| Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial UK Rinne, F Bracco, C Chouza, E Dupont, O Gershanik, JF Marti Masso, ... Drugs 55, 23-30, 1998 | 449 | 1998 |
| Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions MG Murer, G Dziewczapolski, LB Menalled, MC García, Y Agid, ... Annals of Neurology: Official Journal of the American Neurological …, 1998 | 286 | 1998 |
| Levodopa‐induced dyskinesias in Parkinson's disease: clinical and pharmacological classification MR Luquin, O Scipioni, J Vaamonde, O Gershanik, JA Obeso Movement disorders: official journal of the Movement Disorder Society 7 (2 …, 1992 | 273 | 1992 |
| Expanded and independent validation of the movement disorder society–unified Parkinson’s disease rating scale (MDS-UPDRS) P Martinez-Martin, C Rodriguez-Blazquez, M Alvarez-Sanchez, T Arakaki, ... Journal of neurology 260, 228-236, 2013 | 250 | 2013 |
| Behavioral correlations of dopamine receptor activation O Gershanik, RE Heikkila, RC Duvoisin Neurology 33 (11), 1489-1489, 1983 | 217 | 1983 |
| Action-verb processing in Parkinson’s disease: new pathways for motor–language coupling JF Cardona, O Gershanik, C Gelormini-Lezama, AL Houck, S Cardona, ... Brain Structure and Function 218, 1355-1373, 2013 | 189 | 2013 |
| The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study F Bracco, A Battaglia, C Chouza, E Dupont, O Gershanik, JFM Masso, ... CNS drugs 18, 733-746, 2004 | 177 | 2004 |
| Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa UK Rinne, F Bracco, C Chouza, E Dupont, O Gershanik, JFM Masso, ... Neurology 48 (2), 363-368, 1997 | 177 | 1997 |
| Motor-language coupling: direct evidence from early Parkinson’s disease and intracranial cortical recordings A Ibáńez, JF Cardona, YV Dos Santos, A Blenkmann, P Aravena, M Roca, ... cortex 49 (4), 968-984, 2013 | 172 | 2013 |
| Assessing the non‐motor symptoms of Parkinson's disease: MDS‐UPDRS and NMS Scale P Martinez‐Martin, KR Chaudhuri, JM Rojo‐Abuin, ... European Journal of Neurology 22 (1), 37-43, 2015 | 149 | 2015 |
| Impairments in social cognition in early medicated and unmedicated Parkinson disease M Roca, T Torralva, E Gleichgerrcht, A Chade, GG Arévalo, O Gershanik, ... Cognitive and Behavioral Neurology 23 (3), 152-158, 2010 | 144 | 2010 |
| Levodopa in the treatment of Parkinson's disease: a consensus meeting Y Agid, E Ahlskog, A Albanese, D Calne, T Chase, J De Yebenes, ... Movement disorders 14 (6), 911-913, 1999 | 129 | 1999 |
| Neuropsychological disturbances in hemiparkinson's disease S Starkstein, R Leiguarda, O Gershanik, M Berthier Neurology 37 (11), 1762-1762, 1987 | 117 | 1987 |
| Polysomnographic measures in Parkinson's disease: a comparison between patients with and without REM sleep disturbances. TC Wetter, C Trenkwalder, O Gershanik, B Högl Wiener klinische Wochenschrift 113 (7-8), 249-253, 2001 | 110 | 2001 |
| A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease BE Höl, G Gomez-Arevalo, S Garcia, O Scipioni, M Rubio, M Blanco, ... Neurology 50 (5), 1332-1339, 1998 | 110 | 1998 |
| How embodied is action language? Neurological evidence from motor diseases JF Cardona, L Kargieman, V Sinay, O Gershanik, C Gelormini, L Amoruso, ... Cognition 131 (2), 311-322, 2014 | 105 | 2014 |
| Differences in MDS‐UPDRS scores based on Hoehn and Yahr stage and disease duration M Skorvanek, P Martinez‐Martin, N Kovacs, M Rodriguez‐Violante, ... Movement disorders clinical practice 4 (4), 536-544, 2017 | 103 | 2017 |
